C&L: John Johnson to run ImClone

ImClone Systems appointed John Johnson as CEO, filling shoes emptied by Carl Icahn's move to oust top management.

Alpine Biomed Corporation has named John Arnott, a former officer with Hospira, as chief executive officer.

Bradmer Pharmaceuticals has promoted DR. Alan M. Ezrin, Ph.D., to CEO from COO. Brian Brohman, CFO, has taken on the additional role of chief business officer.

Robert Coughlin has been named as the new president of the Massachusetts Biotechnology Council. He recently served as an aide to the governor.

Aeterna Zentaris has appointed Jurgen Ernst as chairman of the board of directors and David J. Mazzo, Ph.D., the company's president and CEO, to its board of directors,

WuXi PharmaTech has added three senior level positions to its management: Edward Hu as executive vice president of operations, Victor Chen as vice president and head of toxicology, SuZhou PharmaTech, and Christine Lu-Wong as WuXi PharmaTech VP of Finance.

Biogen Idec has named Paul Clancy as its new CFO.

Neurotech Pharmaceutical has appointed Richard Small as vice president and chief financial officer.

IntelGenx Technologies has named Gino Di Iorio as its CFO.

Vyteris has appointed Anthony J. Cherichella as chief financial officer and principal accounting officer.

Protherics has named Rolf Soderstrom as finance director.

Tikvah Therapeutics has named Jack W. Callicutt to the position of vice president and chief financial officer.

Theratechnologies has named Pierre Caudrelier, M.D., as chief medical officer.

PharmEng International has named David G. Leonard as Keata Pharma president for the Sydney and Perth manufacturing sites.

MAP Pharmaceuticals has promoted Stephen Shrewsbury to chief medical officer, a newly created job.

BioDelivery Sciences International has hired David Blum, M.D. as vice president of medical affairs and clinical research, a newly created position

Clinsys Clinical Research has named Hartmut Schmied, MD as vice president, European operations based in the company's Dusseldorf, Germany facility.

Affymax announced that Robert F. Venteicher, Ph.D. has joined the company as vice president, technical operations.

Medivation today announced that it has appointed Robert Elfont, M.D., Ph.D., as vice president of clinical development

Cytochroma announced that Joel Z. Melnick, MD has joined Cytochroma's management team as vice president, clinical & regulatory affairs.

Eleanor de Groot, PhD, has been promoted to vice president of technical operations for Sapphire Therapeutics. Brenda Marczi, PharmD, MBA, has joined Sapphire Therapeutics as vice president regulatory affairs. Richard V. Nelson, PhD, has been promoted to vice president of project planning and management.

Sysmex America announced that former Beckman Coulter Executive Ralph Taylor has been named as the company's vice president of marketing and medical affairs.

TyRx Pharma has hired Mark Citron as vice president, clinical and regulatory affairs. Citron replaces Mason Diamond, DDS, who has elected to pursue other opportunities.

PAREXEL Consulting has appointed Dr. Hans Van Bronswijk to the position of principal consultant in its European Drug Development Practice.

Kendle has named Timothy Forsey principal regulatory affairs consultant.

SCOLR Pharma announced that Bruce S. Morra, Ph.D., M.B.A. has been appointed to the company's board of directors.

OLIGOMERIX announced that Victor P. Micati has been appointed to the company's board of directors.

Seahorse Bioscience has named Joseph Keegan to the company's board of directors.

ProtoKinetix has named Max Arella, PhD, to their board.

ImmunoCellular Therapeutics said that Dr. Rudolph H. Nisi resigned as a director for personal reasons.

Inforsense has named Stephen Allott as executive chairman of the board of directors.

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.